Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Autor: Sagar Lonial, Al-Ola Abdallah, Faiz Anwer, Ashraf Z. Badros, Manisha Bhutani, Abdullah Khan, Brea Lipe, Albert Oriol, Darrell White, Michael Amatangelo, Kexin Jin, Mark Masin, Vi Nguyen, Alpesh Amin, Paulo Maciag, Niels WCJ Van De Donk

Publikováno v: Blood. 140:4398-4400

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60917a747dbd2b683e5c485c4f641ace
https://doi.org/10.1182/blood-2022-158180

Model-Based Meta-analysis for the Population Pharmacokinetics of Iberdomide and Its Major Active Metabolite in Healthy Subjects and Subjects with Relapse and Refractory Multiple Myeloma

Autor: Yiming Cheng, Yongjun Xue, Lu Chen, Mark Masin, Paulo Maciag, Teresa Peluso, Simon Zhou, Yan Li

Aim A parent-metabolite population pharmacokinetic (popPK) model of iberdomide was developed and the influence of demographic and disease-related covariates on popPK parameters was assessed based on data from three clinical studies of iberdomide (dos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::378df962cd503bfcfb58b8a42647a94f
https://doi.org/10.22541/au.164873552.25498797/v1

P-231: Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial

Autor: Michael Amatangelo, Yiming Cheng, William Pierceall, Niels W.C.J. van de Donk, Sagar Lonial, Maria Wang, Joshua Emerson, Kevin Hong, Paulo Maciag, Teresa Peluso, Anita Gandhi, Anjan Thakurta

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S162

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d0c886356ae2d7ea6e0d1f110d4c1753
https://doi.org/10.1016/s2152-2650(22)00561-4

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Autor: Javier de la Rubia, Shaji Kumar, Xiaoqing Yang, Kevin J. Freise, Hans Salwender, Philippe Moreau, Elizabeth Punnoose, Rakesh Popat, Paulo Maciag, Muhammad Jalaluddin, Michele Cavo, Anjla Sood, Vania Hungria, Jeremy A. Ross, James E. Ward, Cristina Gasparetto, Kenshi Suzuki, Simon J. Harrison, Inho Kim, Wan Jen Hong

Publikováno v: LANCET ONCOLOGY
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-FISABIO. Repositorio Institucional de Producción Científica
instname

Background Venetoclax is a highly selective, potent, oral BCL-2 inhibitor, which induces apoptosis in multiple myeloma cells. Venetoclax plus bortezomib and dexamethasone has shown encouraging clinical efficacy with acceptable safety and tolerability

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c70642248b89840cae5eaa84e9035a54
http://hdl.handle.net/11585/804156

CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002

Autor: Nizar J. Bahlis, Irwindeep Sandhu, Teresa Peluso, Cesar Rodriguez, Tiziana Civardi, Richard Leblanc, Jessica Katz, Michael Amatangelo, Manisha Lamba, Paul G. Richardson, Zehua Zhou, Enrique M. Ocio, Meletios A. Dimopoulos, Paulo Maciag, Aurore Perrot, Noopur Raje, Ralph Wäsch, Darrell White, Tara K. Gregory, Suzanne Trudel, Marc-Steffen Raab, Albert Oriol

Publikováno v: Blood. 138:2731-2731

Introduction: CC-92480 is a potent, novel CELMoD ® compound designed for rapid and maximal degradation of Ikaros and Aiolos, that has shown immunostimulatory effects and enhanced tumoricidal activity in myeloma cells, including those resistant to le

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d075abd4ac33c65449e4858faa7f8ea9
https://doi.org/10.1182/blood-2021-147812